Results 241 to 250 of about 539,919 (309)

Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface

Advanced Science, EarlyView.
This study identifies a cancer‐specific interaction between CD47 and integrin αvβ3 that facilitates immune evasion. A rationally designed peptide, PSFL‐NK13, disrupts this axis, enhancing macrophage‐mediated phagocytosis and suppressing tumor growth without inducing anemia.
Peng‐Cheng Yu, Chen‐Xi Yue, Wen‐Zhong Dong, Cui‐Yun Hao, Yi‐Fan Qiao, Di Liu, Xin Zhang, Qi Zhan, Jia‐Bao Yao, Dong‐Ping Wang, Peng Cao, Ying‐Zhe Fan, Ye Yu   +12 more
wiley   +1 more source

Dendritic Cell-Derived Exosomes: Next Generation of Cancer Immunotherapy. [PDF]

Biomedicines
Dhar R, Sonar S, Das A, Tajul Akmal NAS, Hawa Jasni A, Rmt Balasubramaniam V, Narayanan K, Subramaniyan V.   +7 more
europepmc   +1 more source

NLRP4-ER Stress-CCL5 axis as a translational target for NK cell-based immunotherapy in lung cancer

Wang Hui, Lu Yuting
openalex   +1 more source

Predicting Immunotherapy Outcomes in NSCLC Using RNA and Pathology from Multicenter Clinical Trials

Advanced Science, EarlyView.
LIRA, a machine learning‐based model, is developed using transcriptomic data from 891 NSCLC patients in the OAK and POPLAR cohorts. Its predictive performance is validated in multiple external cohorts. Patients stratified by LIRA‐score exhibit distinct clinical characteristics and tumor microenvironment profiles.
Zhaojun Wang, Yiran Fang, Xiatong Huang, Guichuang Ma, Qianqian Mao, Xiansheng Lu, Guangda Rong, Yunfang Yu, Yuanyuan Wang, Zhenhua Huang, Huiying Sun, Jiani Wu, Wenchao Gu, Na Huang, Jianhua Wu, Rui Zhou, Xiaoxiang Rong, Siting Zheng, Shaowei Li, Gaofeng Wang, Ling Wang, Wenjun Qiu, Luyang Jiang, Peng Luo, Yonggang Liu, Jianping Bin, Yulin Liao, Min Shi, Zuqiang Wu, Jiguang Wang, Wangjun Liao, Gang Chen, Dongqiang Zeng   +32 more
wiley   +1 more source

Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy. [PDF]

Immunotargets Ther
Silva-Romeiro S, Flores-Campos RDC, Sánchez-León ML, Sánchez-Margalet V, De la Cruz-Merino L.   +4 more
europepmc   +1 more source

Dynamic Arginine Methylation of YBX1 Relay Controls Its Phase Separation and Chemoradiotherapy Resistance in Rectal Cancer

Advanced Science, EarlyView.
Protein arginine methyltransferase 3 (PRMT3) induces the arginine methylation of Y‐box binding protein 1 (YBX1), which suppresses phase separation and is imperative for its nuclear translocation. Subsequently, lysine‐specific demethylase 4A demethylates YBX1 to unmask the R247 residue and promote its phase separation, which transcriptionally regulates ...
Yunxing Shi, Taixuan Wan, Shaoru Liu, Huashan Liu, Ziwei Zeng, Wenxin Li, Zhenxing Liang, Li Xiong, Shuanglin Luo, Yunfei Yuan, Liang Huang, Liang Kang   +11 more
wiley   +1 more source

Breaking barriers: The cGAS-STING pathway as a novel frontier in cancer immunotherapy. [PDF]

Cancer Commun (Lond)
Yan Y, Tan X, Song B, Yi M, Chu Q, Wu K.
europepmc   +1 more source

Sanggenol L Enhances Temozolomide Drug Sensitivity by Inhibiting Mitophagy and Inducing Apoptosis Through the Regulation of the TRIM16‐OPTN Axis in Glioblastoma

Advanced Science, EarlyView.
Sanggenol L, a flavonoid from mulberry, enhances glioblastoma sensitivity to temozolomide by inhibiting mitophagy and inducing apoptosis through TRIM16‐mediated OPTN degradation. In animal studies, liposomal delivery of Sanggenol L significantly improves the efficacy of its combination with TMZ, providing new insights into glioblastoma treatment ...
Hongbo Chang, Jianbing Hou, Xin Hu, Nana Hou, Minghao Xu, Yi Du, Jingyang Xu, Yongzhao Wang, Zhuohao Xie, Junbo Shi, Yundong Zhang, Hongjuan Cui   +11 more
wiley   +1 more source

Non-coding RNAs in gastric cancer immunotherapy: mechanisms and clinical implications. [PDF]

Front Immunol
Dong H, Ye C, Yu X, Shao Y.
europepmc   +1 more source

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

Advanced Science, EarlyView.
IDH‐mutant gliomas exhibit sensitivity to PARP inhibitors (PARPi) owing to oncometabolite 2‐HG‐induced DNA repair defects. PARPi treatment induces resistance by upregulating Prickle4, which promotes VEGF‐driven angiogenesis. Combining PARPi veliparib with anti‐angiogenic lenvatinib blocks this pathway, causing tumor regression and prolonged survival in
Ju Yang, Hua Yang, Yifan Yuan, Chenyang Zhang, Ziwei Fu, Yanyan Chen, Yinghong Xiong, Shuyu Chen, Kexin Ling, Ying Liu, Jason T. Huse, Bo Chen, Timothy A. Chan, Zengxin Qi, Zhao Zhang, Xiuping Liu, Yuxiang Wang   +16 more
wiley   +1 more source